United States Drug Manufacturers - General news

08:07 25 Jul 2026

Investing.com Earnings Main company 🇺🇸 United States

AbbVie stock may move 4.2% on July 31 earnings report

AbbVie Inc. (NYSE:ABBV) stock is projected to move by 4.2% based on options data ahead of its July 31 earnings release. Historically, the stock's actual movement has often exceeded the implied move from options. The article details past earnings announcement performances, noting instances where …

ABBV main company

Sharemaestro market context Trend signal active 52 weeks +21.3% · Next-week setup positive 57.6%

06:40 25 Jul 2026

AD HOC NEWS Balance sheet Main company 🇺🇸 United States

Grifols stock steadies as leverage reduction and earnings trends shape investor focus

Grifols stock performance is currently being shaped by the company's efforts to reduce debt and recent earnings trends. The company, a Barcelona-based plasma specialist, is focusing on deleveraging, improving operating margins, and generating strong cash flow to reassure investors and stabilize its share price. …

GRFS main company

Sharemaestro market context Price below Trend Line 52 weeks -23.4%

04:21 25 Jul 2026

GlobeNewswire Earnings Main company 🇺🇸 United States

Press Release: Sanofi announces decision not to submit amlitelimab in atopic dermatitis for global regulatory reviews

Sanofi announced it will not submit amlitelimab for global regulatory reviews in moderate-to-severe atopic dermatitis, discontinuing its clinical development for this indication. The decision follows a strategic assessment where the drug, despite some positive results in a long-term extension study, was deemed not to …

SNY main company

Sharemaestro market context Price below Trend Line 52 weeks -10.1% · Next-week setup positive 56.1%

02:37 25 Jul 2026

Yahoo! Finance Canada Earnings Main company 🇺🇸 United States

Amgen Inc. (AMGN) Stock Price, News, Quote & History

This Yahoo Finance page provides comprehensive financial information for Amgen Inc. (AMGN), including its current stock price, recent trading activity, key events, and detailed financial metrics. It also offers an overview of the company's business, product portfolio, and analyst insights, along with tools for …

AMGN main company

Sharemaestro market context Trend signal active 52 weeks +44.4%

00:41 25 Jul 2026

TradingKey Earnings Main company 🇺🇸 United States

MIRA|Mira Pharmaceuticals Inc|Price:0.882|Chg%:-0.046

Mira Pharmaceuticals Inc (MIRA) closed at $0.882, down 4.97% on July 24th, 2026. The company, a clinical-stage pharmaceutical firm, focuses on developing therapeutics for neurological, neuropsychiatric, and metabolic disorders, including Ketamir-2 and SKNY-1 in its pipeline. Despite strong fundamentals and high growth potential, the …

MIRA main company

Sharemaestro market context Price below Trend Line 52 weeks -45.4%

00:37 25 Jul 2026

TradingView Earnings Main company 🇺🇸 United States

Bristol-Myers Squibb Company Celegne Contingent Value Revenue Breakdown – BOATS:CELG/R

This article provides a brief overview of Bristol-Myers Squibb Company's Celgene Contingent Value financials, specifically focusing on its revenue breakdown for the Innovative Medicines segment and geographical contributions. Last year, the company generated $48.19 billion USD from Innovative Medicines, with the largest portion, $33.28 …

BMY main company

Sharemaestro market context Trend signal active 52 weeks +38.1%

23:12 24 Jul 2026

Yahoo! Finance Canada Earnings Main company 🇺🇸 United States

Johnson & Johnson (JNJ) Reports Early Phase 3 Win In Multiple Myeloma

Johnson & Johnson announced highly positive interim Phase 3 results for its TECVAYLI + TALVEY combination therapy for relapsed or refractory multiple myeloma, leading to early unblinding of the trial. The regimen significantly reduced the risk of disease progression and death, reinforcing Johnson & …

JNJ main company

Sharemaestro market context Trend signal active 52 weeks +48.8%

23:12 24 Jul 2026

TradingView Earnings Main company 🇺🇸 United States

Novartis AG Sponsored ADR Revenue Breakdown – SWB:NOTA

Novartis AG Sponsored ADR (SWB:NOTA) generated €46.43 billion in revenue last year. Its top-performing segment was Oncology, contributing €14.33 billion. The company's largest regional contribution came from the United States, accounting for €19.86 billion.

NVS main company

Sharemaestro market context Trend signal active 52 weeks +22.5% · Next-week setup positive 61.2%

23:08 24 Jul 2026

MarketWatch Market update Main company 🇺🇸 United States

Gilead Sciences Inc. stock underperforms Friday when compared to competitors

Gilead Sciences Inc. (GILD) saw its stock slide by 1.18% on Friday, closing at $129.31 despite a generally favorable day for the stock market, where the S&P 500 Index and Dow Jones Industrial Average both rose. This performance broke a two-day winning streak for …

GILD main company

Sharemaestro market context Price above Trend Line 52 weeks +23.7%

22:38 24 Jul 2026

Market source Earnings Main company 🇺🇸 United States

Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know

Gilead Sciences (GILD) stock experienced a 1.18% decline, closing at $129.31, underperforming the broader S&P 500. Despite this recent dip, the stock has seen a 5.67% increase over the past month. The company is set to report its earnings on August 4, 2026, with …

GILD main company

Sharemaestro market context Price above Trend Line 52 weeks +23.7%

20:56 24 Jul 2026

Scrip Deals and strategy Main company 🇺🇸 United States

Merck Signs License Agreements For Monthly PrEP Drug Alimatravir In Developing Countries

Merck has signed license agreements for its monthly PrEP drug, Alimatravir, to be developed and distributed in developing countries. This move aims to make the preventive HIV medication more accessible in regions with higher needs. The article details this strategic business decision by Merck, …

MRK main company

Sharemaestro market context Trend signal active 52 weeks +60.7%

17:44 24 Jul 2026

TipRanks Market update Main company 🇺🇸 United States

Bristol-Myers Squibb Expands Pipeline With New First-in-Human Trial for BMS-986533

Bristol-Myers Squibb (BMY) has initiated a first-in-human Phase 1 trial for BMS-986533, an oral drug, to evaluate its safety, pharmacokinetics, and dosing in healthy volunteers. This randomized, double-blind, placebo-controlled study includes multiple dosing schemes and assesses interactions with common medications. The trial, which began …

BMY main company

Sharemaestro market context Trend signal active 52 weeks +38.1%

17:35 24 Jul 2026

MarketWatch Earnings Main company 🇺🇸 United States

Amgen Inc. stock underperforms Friday when compared to competitors despite daily gains

Amgen Inc. (AMGN) shares rose 1.22% on Friday, closing at $376.04. Despite this daily gain, the stock underperformed compared to the broader market, as the S&P 500 Index increased by 0.05% and the Dow Jones Industrial Average rose by 0.46%. This marks the second …

AMGN main company

Sharemaestro market context Trend signal active 52 weeks +44.4%

17:08 24 Jul 2026

TradingView Earnings Main company 🇺🇸 United States

Merck & Co., Inc. Revenue Breakdown – VIE:MRK

Merck & Co., Inc. (VIE:MRK) generated €55.35 billion in revenue last year, with its Pharmaceutical segment contributing the majority at €49.50 billion. The United States was the largest regional contributor, accounting for €31.09 billion. This data provides a breakdown of the company's financial performance …

MRK main company

Sharemaestro market context Trend signal active 52 weeks +60.7%

16:45 24 Jul 2026

BioPharma Dive Market update Main company 🇺🇸 United States

Novo escalates legal fight with Lilly; J&J reinforces ‘dominance’ in multiple myeloma

Novo Nordisk has escalated its legal dispute with Eli Lilly, seeking an injunction to stop allegedly "misleading" obesity drug advertisements. Meanwhile, Johnson & Johnson reported strong results for a multiple myeloma drug combination, Revolution Medicines' pancreatic tumor medicinedaraxonrasib was accepted for FDA review, and …

LLY main company

Sharemaestro market context Trend signal active 52 weeks +66.6% · Next-week setup positive 58.3%

16:42 24 Jul 2026

BioPharma Dive Deals and strategy Main company 🇺🇸 United States

Sanofi halts development of troubled immune drug in eczema

Sanofi has halted the development of amlitelimab, an experimental eczema drug it once considered a potential successor to Dupixent, due to mixed late-stage study results and safety concerns. This decision follows similar setbacks for other OX40L-targeting antibodies and raises questions about Sanofi's research pipeline, …

SNY main company

Sharemaestro market context Price below Trend Line 52 weeks -10.1% · Next-week setup positive 56.1%

16:40 24 Jul 2026

Fierce Biotech Deals and strategy Main company 🇺🇸 United States

Sanofi abandons plan to seek approval for eczema drug from $1.1B Kymab buyout

Sanofi has decided to abandon its plans to seek approval for amlitelimab, an eczema drug acquired through its $1.1 billion Kymab buyout, for atopic dermatitis. The company stated that the drug would not offer a "meaningful improvement" over existing treatments, despite previous phase 3 …

SNY main company

Sharemaestro market context Price below Trend Line 52 weeks -10.1% · Next-week setup positive 56.1%

16:40 24 Jul 2026

WSJ Regulatory and legal Main company 🇺🇸 United States

Sanofi to Drop Eczema Drug Amid Review of Pipeline Under New CEO

Sanofi has announced it will not seek regulatory approval for its eczema drug, amlitelimab, after data review indicated it doesn't support further development. This decision comes as the French pharmaceutical company undergoes a pipeline review under its new chief executive. While the eczema application …

SNY main company

Sharemaestro market context Price below Trend Line 52 weeks -10.1% · Next-week setup positive 56.1%

16:12 24 Jul 2026

BioSpace Deals and strategy Main company 🇺🇸 United States

Sanofi’s $1.4B Kymab bet falters again as atopic dermatitis trials scrapped

Sanofi has scrapped most of its ongoing trials for amlitelimab, an autoimmune asset acquired from Kymab, in atopic dermatitis following its failure to significantly improve over the standard of care in Phase 3 studies. This decision, part of a strategic pipeline assessment, comes despite …

SNY main company

Sharemaestro market context Price below Trend Line 52 weeks -10.1% · Next-week setup positive 56.1%

16:11 24 Jul 2026

The Globe and Mail Deals and strategy Main company 🇺🇸 United States

Scilex Announces Strategic Sale of Vivasor Preferred Shares

Scilex Holding Company has announced the strategic sale of over 6.4 million shares of Vivasor’s Series A-1 and A-2 preferred stock back to Vivasor Holding Company. The transaction, valued at approximately $12 million, will be paid to Scilex in multiple tranches through June 30, …

SCLX main company

Sharemaestro market context Trend signal active 52 weeks -42.5% · Next-week setup negative 43.9%

15:54 24 Jul 2026

Seeking Alpha Regulatory and legal Main company 🇺🇸 United States

J&J, Gilead among recipients of EU drug nods this week (JNJ)

The European Medicines Agency's expert panel endorsed 12 new medicines and eight label expansions this week, impacting major pharmaceutical companies. Johnson & Johnson and Gilead are among the U.S. drugmakers receiving positive recommendations for their products. These approvals could allow J&J to enter the …

GILD main company

Sharemaestro market context Price above Trend Line 52 weeks +23.7%

15:50 24 Jul 2026

Fierce Pharma Regulatory and legal Main company 🇺🇸 United States

Amgen hands in data package in hopes of FDA hearing for Tavneos defense

Amgen has submitted a data package to the FDA to defend the approval of its ANCA-associated vasculitis drug, Tavneos, which it acquired from ChemoCentryx. The drug faces regulatory scrutiny due to safety flags and concerns about its pivotal trial. Amgen is seeking a hearing …

AMGN main company

Sharemaestro market context Trend signal active 52 weeks +44.4%

15:42 24 Jul 2026

Investing.com Market update Main company 🇺🇸 United States

GSK admits 70,759 shares to trading on London Stock Exchange

GSK plc announced the admission of 70,759 ordinary shares to trading on the London Stock Exchange's Main Market. These shares, part of the GlaxoSmithKline plc Share Save Plan 2022, bring the total number of GSK ordinary shares admitted to trading to 4,316,292,310. The newly …

GSK main company

Sharemaestro market context Price below Trend Line 52 weeks +26.3% · Next-week setup positive 55.6%

15:40 24 Jul 2026

TradingView Earnings Main company 🇺🇸 United States

Grifols, S.A. Pref Class B Revenue Breakdown – LSX:A2ABZN

Grifols, S.A. Pref Class B (LSX:A2ABZN) generated 7.52 billion EUR in revenue last year. The Biopharma segment was the top-performing segment, contributing 6.49 billion EUR, an increase from 6.14 billion EUR the previous year. The majority of the company's revenue, 4.25 billion EUR, came …

GRFS main company

Sharemaestro market context Price below Trend Line 52 weeks -23.4%

15:40 24 Jul 2026

Stock Titan Market update Main company 🇺🇸 United States

GSK plc (GSK) adds 70,759 Share Save Plan shares to London listing

GSK plc has announced the admission of 70,759 new ordinary shares to trading on the London Stock Exchange Main Market. These shares are part of the GlaxoSmithKline plc Share Save Plan 2022 and are fully fungible with existing shares. Following this admission, the total …

GSK main company

Sharemaestro market context Price below Trend Line 52 weeks +26.3% · Next-week setup positive 55.6%

15:37 24 Jul 2026

TradingView Deals and strategy Main company 🇺🇸 United States

Biogen Q2 Earnings: Can New Drugs Counter Falling MS Sales?

Biogen is expected to surpass analyst expectations for its Q2 2026 earnings, despite anticipated declines in sales of its established MS drugs like Tecfidera and Tysabri due to generic and biosimilar competition. The company's sales are projected to be bolstered by new product growth …

BIIB main company

Sharemaestro market context Trend signal active 52 weeks +50.6% · Next-week setup positive 55.3%

15:37 24 Jul 2026

TradingView Earnings Main company 🇺🇸 United States

Amgen Inc. Revenue Breakdown – HAN:AMG

Amgen Inc. generated €31.29 billion in revenue last year, with Human Therapeutics being its highest-performing segment at €29.93 billion. The United States was the largest regional contributor, accounting for €22.49 billion of the company's revenue. These figures show a slight decrease in overall revenue …

AMGN main company

Sharemaestro market context Trend signal active 52 weeks +44.4%

15:06 24 Jul 2026

Market source Earnings Main company 🇺🇸 United States

AbbVie (ABBV) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

AbbVie (ABBV) is expected to report a year-over-year increase in earnings and higher revenues for the quarter ended June 2026, with results anticipated on July 31. The consensus EPS estimate is $3.66 per share (+23.2% year-over-year) and revenues are projected at $16.81 billion (+9%). …

ABBV main company

Sharemaestro market context Trend signal active 52 weeks +21.3% · Next-week setup positive 57.6%

14:50 24 Jul 2026

Pharmaceutical Technology Earnings Main company 🇺🇸 United States

Sanofi abandons eczema drug approval efforts in another blow to OX40 class

Sanofi has decided to discontinue the development of its immunology therapy, amlitelimab, for atopic dermatitis (AD), citing a lack of meaningful differentiation from existing treatments. This decision is a setback for Sanofi, which had hoped amlitelimab would succeed its blockbuster drug Dupixent, and further …

SNY main company

Sharemaestro market context Price below Trend Line 52 weeks -10.1% · Next-week setup positive 56.1%

14:46 24 Jul 2026

Reuters Market update Main company 🇺🇸 United States

Amgen submits new data to challenge FDA's proposal to withdraw Tavneos

Amgen has submitted new data to the FDA to challenge the proposed withdrawal of its rare-disease drug Tavneos from the U.S. market. The company argues that over 70 real-world studies involving more than 2,200 patients support the drug's effectiveness and safety, despite the FDA's …

AMGN main company

Sharemaestro market context Trend signal active 52 weeks +44.4%

14:42 24 Jul 2026

STAT Market update Main company 🇺🇸 United States

Fatal gene-editing trial in China raises ethics and oversight questions

A six-year-old girl has died in China after receiving an experimental, brain-directed CRISPR therapy, sparking significant ethical and oversight concerns. This tragic event was reported in conjunction with other biotech news, including an FDA panel narrowly voting to allow compounding pharmacies to produce certain …

SNY main company

Sharemaestro market context Price below Trend Line 52 weeks -10.1% · Next-week setup positive 56.1%

14:31 24 Jul 2026

Ad-hoc-news.de Earnings Main company 🇺🇸 United States

Merck stock steadies as Keytruda drives Q1 2026 revenue growth

Merck & Co.'s stock is primarily driven by its oncology blockbuster Keytruda, which continues to propel revenue growth in Q1 2026. The company is investing billions in R&D to expand its pipeline beyond Keytruda, while also maintaining a significant cash return program. Keytruda remains …

MRK main company

Sharemaestro market context Trend signal active 52 weeks +60.7%

13:58 24 Jul 2026

Seeking Alpha Regulatory and legal Main company 🇺🇸 United States

Merck signs licensing deals for new HIV pill (MRK:NYSE)

Merck has announced seven licensing agreements with generic drug manufacturers, including Viatris, to expand access to its investigational HIV pill, alimatravir. These agreements are aimed at making the drug available in low- and middle-income countries. Three of the companies involved are from sub-Saharan Africa, …

MRK main company

Sharemaestro market context Trend signal active 52 weeks +60.7%

13:45 24 Jul 2026

TradingView Deals and strategy Main company 🇺🇸 United States

Organon & Co. Shareholders Clear Sun Pharma Merger Deal

Organon & Co. shareholders have approved the proposed merger agreement with Sun Pharmaceutical Holdings USA, Inc. at a special virtual meeting. Shareholders also passed a non-binding advisory vote regarding compensation for executive officers in connection with the merger. The final voting results will be …

OGN main company

Sharemaestro market context Trend signal active 52 weeks +46.5%

13:10 24 Jul 2026

Dermatology Times Market update Main company 🇺🇸 United States

Sanofi Discontinues Development of OX40L Inhibitor Amlitelimab in Atopic Dermatitis

Sanofi has discontinued the clinical development of amlitelimab for moderate to severe atopic dermatitis (AD), citing insufficient efficacy and safety data to significantly improve upon current standard-of-care treatments. Despite long-term data from the ESTUARY study showing durable maintenance of clinical response, Sanofi concluded that …

SNY main company

Sharemaestro market context Price below Trend Line 52 weeks -10.1% · Next-week setup positive 56.1%

12:53 24 Jul 2026

Benzinga Earnings Main company 🇺🇸 United States

CNBC ‘Final Trades’: Netflix, AbbVie, Cerebras Systems - Netflix (NASDAQ:NFLX), CrowdStrike Holdings (NAS

This article summarizes the "Final Trades" segment on CNBC, highlighting stock picks from various financial experts. Recommendations include AbbVie (ABBV) with a raised price target, Transocean (RIG) ahead of earnings, Cerebras Systems (CBRS) due to a new cybersecurity partnership with CrowdStrike (CRWD), and Netflix …

ABBV main company

Sharemaestro market context Trend signal active 52 weeks +21.3% · Next-week setup positive 57.6%